Because blood stage infections produce most clinical manifestations of malaria, drug development has primarily focused on the development of schizonticides targeting Plasmodium falciparum, the causative agent of the most severe form of human malaria. Increased funding and a growing awareness of the problem of parasite resistance have helped to push a number of new schizonticides into the developmental pipeline and even clinical trials. On the other hand, few of these drug candidates are effective against malaria exoerythrocytic stages, and even fewer are likely to provide a radical cure for P. vivax malaria. The need for drugs which can act as a replacement for primaquine is even more urgent as malaria eradication becomes a higher priority for the world health community. In order to stimulate drug development activity against hepatic stages, more work is needed to understand hepatic stage biology and to discover targets whose activity is essential for both hepatic and blood stage development. I will use a chemical genetic approach to investigate pathways that are critically essential to both blood and hepatic parasite development and then characterize the target(s) revealed by this approach. Specifically, I will grow parasites under sub-lethal concentrations of small molecules with activity against blood and hepatic stage parasites until the parasites acquire low level resistance to the small molecules. I will use genome-scanning to determine the likely target(s). Mutations will be engineered into sensitive parasite strains to prove that they cause resistance. Likely targets will be further characterized using immuno and electron microscopy and localization studies, as well as disruption studies. The work may lead to a better understanding of how to treat tissue stage malaria, provide new antibiotic resistance genes, and provide information about how eukaryotic pathogens become resistant to drugs.

Public Health Relevance

Many antimalarial drugs alleviate symptoms but do not necessarily result in a complete cure because some malaria parasites are able to persist asymptomatically in the liver for months or years. The inability to eliminate cryptic liver forms creates a barrier to malaria eradication. We propose to find new targets that are critical to the liver stages as well as the blood stages with the long term aim of designing better drugs.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI090141-01A1
Application #
8204290
Study Section
Special Emphasis Panel (ZRG1-IDM-S (03))
Program Officer
Rogers, Martin J
Project Start
2011-05-06
Project End
2012-04-30
Budget Start
2011-05-06
Budget End
2012-04-30
Support Year
1
Fiscal Year
2011
Total Cost
$473,750
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
781613492
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Antonova-Koch, Yevgeniya; Meister, Stephan; Abraham, Matthew et al. (2018) Open-source discovery of chemical leads for next-generation chemoprotective antimalarials. Science 362:
Cowell, Annie N; Istvan, Eva S; Lukens, Amanda K et al. (2018) Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Science 359:191-199
Diedrich, Daniela; Stenzel, Katharina; Hesping, Eva et al. (2018) One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites. Eur J Med Chem 158:801-813
Luth, Madeline R; Gupta, Purva; Ottilie, Sabine et al. (2018) Using in Vitro Evolution and Whole Genome Analysis To Discover Next Generation Targets for Antimalarial Drug Discovery. ACS Infect Dis 4:301-314
Xie, Stanley C; Gillett, David L; Spillman, Natalie J et al. (2018) Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome. J Med Chem 61:10053-10066
Ma, Shang; Cahalan, Stuart; LaMonte, Gregory et al. (2018) Common PIEZO1 Allele in African Populations Causes RBC Dehydration and Attenuates Plasmodium Infection. Cell 173:443-455.e12
Cowell, Annie N; Loy, Dorothy E; Sundararaman, Sesh A et al. (2017) Selective Whole-Genome Amplification Is a Robust Method That Enables Scalable Whole-Genome Sequencing of Plasmodium vivax from Unprocessed Clinical Samples. MBio 8:
Abdel-Haleem, Alyaa M; Lewis, Nathan E; Jamshidi, Neema et al. (2017) The Emerging Facets of Non-Cancerous Warburg Effect. Front Endocrinol (Lausanne) 8:279
LaMonte, Gregory M; Almaliti, Jehad; Bibo-Verdugo, Betsaida et al. (2017) Development of a Potent Inhibitor of the Plasmodium Proteasome with Reduced Mammalian Toxicity. J Med Chem 60:6721-6732
Rabinovich, Regina N; Drakeley, Chris; Djimde, Abdoulaye A et al. (2017) malERA: An updated research agenda for malaria elimination and eradication. PLoS Med 14:e1002456

Showing the most recent 10 out of 42 publications